An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...
An experimental drug originally developed by Sanofi that is now being advanced by the Mayo Clinic significantly curbed ...
Each year, flu vaccines are tailored to match the most prevalent virus strains expected to circulate. Without an official ...
An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. According to Enveda, ...
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
The company has struggled to keep up with the pace of rivals Moderna and Pfizer, which make messenger RNA-based vaccines ...
Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results